07:00 , Oct 20, 1997 |  BC Week In Review  |  Company News

Roche Bioscience management update

Roche Bioscience, Palo Alto, Calif.   Business: Biopharmaceuticals   Hired: Nancy Cohen as VP of legal affairs, formerly general counsel and corporate secretary for Activated Cell Therapy Inc.   ...
07:00 , Sep 8, 1997 |  BC Week In Review  |  Company News

Activated Cell Therapy infectious diseases/aids, cancer news

The company changed its name to Dendreon Corp. to reflect its use of dendritic cells to develop therapies. Dendreon is in Phase I/II trials with dendritic cell therapy in prostate cancer. (Dendreon mezzanine financing,...
07:00 , Jul 7, 1997 |  BC Week In Review  |  Company News

Activated Cell Therapy Inc., Immune Response deal

Activated Cell Therapy acquired an exclusive worldwide license from IMNR to a European patent covering the use of antigen-presenting dendritic cells as cell therapies against B-cell lymphoma. The patent, issued in 1996, was licensed to...
07:00 , Jun 2, 1997 |  BC Week In Review  |  Company News

Activated Cell Therapy Inc., Osiris deal

Osiris will use Activated Cell Therapy's cell isolation and enrichment technology to develop products based on mesenchymal stem cells. Osiris, which has exclusive worldwide rights to the technology for recovery of mesenchymal stem cells, will...
07:00 , May 27, 1997 |  BC Week In Review  |  Clinical News

Dendritic cell therapy: Phase I and II Update

Activated Cell Therapy Inc., Mountain View, Calif.   Product: Dendritic cell therapy   Indication: Advanced prostate cancer   Status: The company began Phase I/II trials in which cells are taken from patients' blood and activated in tissue culture...
08:00 , Jan 13, 1997 |  BC Week In Review  |  Company News

Activated Cell Therapy Inc. board of directors update

Activated Cell Therapy Inc., Mountain View, Calif.   Business: Cancer, Infectious diseases/AIDS   Appointed: Gerardo Canet to director; currently chairman, president and CEO of IntegraMed America Inc., a health services management company.   ...
08:00 , Dec 23, 1996 |  BC Week In Review  |  Company News

Cytogen, Neoprobe deal

CYTO's Cellcor subsidiary (Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic colorectal cancer. Cellcor will receive an up front fee and will record contract revenue on a per patient basis....
07:00 , Sep 9, 1996 |  BC Week In Review  |  Company News

Activated Cell Therapy, BioTransplant deal

BTRN received exclusive worldwide rights to Activated Cell Therapy's bone marrow stem cell isolation and enrichment device in the field of organ transplantation. BTRN will use the device to enhance its AlloMune and XenoMune...
07:00 , Aug 26, 1996 |  BC Week In Review  |  Clinical News

Activated Cell Therapy regulatory update

The FDA granted 510(k) clearance to the company's cell processing devices used for cell isolation and enrichment. The technology allows for the recovery and preparation of stem and dendritic cells from peripheral blood, bone marrow...
07:00 , Jun 10, 1996 |  BC Week In Review  |  Company News

Cytogen, Neoprobe deal

NEOP signed a letter of intent to manufacture its RIGS/ACT activated cell therapy product using the cell processing and development manufacturing facility in Needham, Mass., operated by CYTO's Cellcor subsidiary. NEOP retains exclusive rights to...